LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...
Dyne Therapeutics Inc.-3.02% $1.48B ...